A carregar...
Ramucirumab for the treatment of gastroesophageal cancers
INTRODUCTION: In 2014, the U.S. Food and Drug Administration (FDA) approved ramucirumab for use in the second line setting of advanced or metastatic, gastric or gastroesophageal adenocarcinoma (GEAC) based on the result of Phase III clinical trials; REGARD and RAINBOW. AREAS COVERED: We briefly revi...
Na minha lista:
| Publicado no: | Expert Opin Orphan Drugs |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5001688/ https://ncbi.nlm.nih.gov/pubmed/27570714 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/21678707.2015.1040390 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|